A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

195 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-19

Study Completion Date

2027-09-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

NCT07265921

Advanced Solid Cancer

RECRUITING PHASE1

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

NCT06388902

Advanced Solid Malignancies

SUSPENDED PHASE1

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

NCT05869240

Solid Tumor

UNKNOWN PHASE1/PHASE2

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

NCT06724263

Recurrent Platinum-resistant Epithelial Ovarian Cancer Triple Negative Breast Cancer (TNBC) Cervical Cancers +4 more

NOT_YET_RECRUITING PHASE2

A Study of BRY805 in Participants With Advanced Solid Tumors

NCT06289894

Advanced Solid Tumor

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases. The study is divided into two parts: Phase I and Phase II. The Phase I study is the dose escalation phase. The primary objective is to assess the safety and tolerability of a single administration of BPR-6023021 and to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) based on the occurrence of Dose-Limiting Toxicities (DLTs) associated with BPR-6023021 (if the MTD cannot be determined).The Phase II study is the dose expansion phase. The primary objective is to explore the efficacy of BPR-6023021 at a selected dose level.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase 1:Dose escalation

5 dose levels of BPR-6023021 are tentatively planned for Phase 1

Group Type EXPERIMENTAL

BPR-6023021 for injection

Intervention Type DRUG

BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.

Phase 2: RP2D Cohort

Participants will receive BPR-6023021 for injection at the Recommended Phase 2 Dose (RP2D) determined from the Phase 1 dose escalation study.The dose of BPR-6023021 for injection in Phase 2 is selected based on the Phase 1 monotherapy dose escalation study.

Group Type EXPERIMENTAL

BPR-6023021 for injection

Intervention Type DRUG

BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BPR-6023021 for injection

BPR-6023021 is a Radionuclide conjugated drugs (RDC) targeting bone.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The age should be up to 18 years at the time of signing the informed consent form (ICF);
2. The Eastern Cooperative Oncology Group (ECOG) performance status score should be ≤ 1;
3. The expected survival period should be ≥ 3 months
4. Phase I and phase II: Subjects with advanced solid tumor bone metastases diagnosed by histology or cytology; and the subjects have failed standard treatment, or have no standard treatment, or are intolerant or not applicable to standard treatment
5. Before the first administration, a 99mTc-MDP bone scan diagnosed multiple bone metastases, and at least two site was confirmed by CT or MRI;
6. Have adequate organ and bone marrow functions;
7. For subjects with reproductive capacity, take effective medical contraceptive measures during the study treatment and within 6 months after the last administration;
8. The subjects voluntarily join this study, sign the informed consent form, and can comply with the visit and related procedures stipulated in the protocol.

Exclusion Criteria

1. The washout period before the first administration of the study drug was insufficient.
2. Previous received similar radionuclide internal irradiation treatment.
3. Previous received or planned to receive during the study period semi-body external radiotherapy targeting bone metastases.
4. Known "super bone imaging".
5. Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression.
6. Any cardiovascular or cerebrovascular diseases or cardiovascular risk factors that may affect the treatment of the study drug.
7. Poorly controlled diabetes and hypertension.
9. Had other malignant tumors within 5 years before the first administration.
10. Subjects with severe and/or uncontrolled concomitant diseases.
11. Active hepatitis B or active hepatitis C.
12. Human immunodeficiency virus (HIV) test positive or having a history of acquired immune deficiency syndrome (AIDS); known active syphilis infection.
13. During the screening process before the first administration, the condition deteriorated rapidly, such as significant changes in the investigator's assessment of physical condition, etc.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No